Study: USPSTF Mammogram Recs Based on Inaccurate Information
The number of women who must undergo mammograms to prevent one breast cancer death is lower than stated by the U.S. Preventative Services Task Force, researchers found.
The number of women who must undergo mammograms in order to prevent one breast cancer death is lower than stated by the U.S. Preventative Services Task Force (USPSTF), according to a study published in the March issue of the American Journal of Roentgenology.
The USPSTF used incorrect numbers in their calculations, said researchers, which were then used in 2009 to recommend that women aged 40 to 49 years not receive annual mammograms. It was claimed that the potential harm from the tests outweighed potential benefits. The new recommendation suggested that women consult with their physician regarding when screening should be done.
The erroneous calculation was made on the number of women who were invited to undergo a screening mammography, not the actual number of women who went through with the procedure, according to researchers R. Edward Hendrick and Mark A. Helvie.
The modeling used by the USPSTF showed that 746 women needed to be screened to save one life. When the number of women who underwent the mammogram was used instead of the total number, researchers found that only 84 women needed to be screened annually, between the ages of 40 and 84 years, to save one life.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
